961 PREDICTORS OF EARLY BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY IN MEN WITH PT3N0 PROSTATE CANCER. IMPLICATIONS FOR MULTI-MODAL THERAPIES

[1]  U. Capitanio,et al.  Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. , 2014, European urology.

[2]  F. Montorsi,et al.  Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. , 2013, European urology.

[3]  W. Jackson,et al.  The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[4]  W. Hellstrom,et al.  Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement. , 2013, The journal of sexual medicine.

[5]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[6]  R. Thompson,et al.  Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. , 2012, The Journal of urology.

[7]  F. Montorsi,et al.  Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. , 2012, European urology.

[8]  F. Montorsi,et al.  High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. , 2012, International journal of radiation oncology, biology, physics.

[9]  F. Montorsi,et al.  Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. , 2012, European urology.

[10]  F. Montorsi,et al.  Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. , 2012, European journal of cancer.

[11]  L. Kestin,et al.  Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Sandler,et al.  Interval to biochemical failure as a biomarker for cause‐specific and overall survival after dose‐escalated external beam radiation therapy for prostate cancer , 2012, Cancer.

[13]  R. Orecchia,et al.  Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[14]  F. Montorsi,et al.  Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. , 2011, European urology.

[15]  U. Capitanio,et al.  Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. , 2011, European urology.

[16]  M. Blute,et al.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. , 2011, European urology.

[17]  J. Dimopoulos,et al.  Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy? , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Pierre I Karakiewicz,et al.  Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. , 2009, The Journal of urology.

[20]  P. Carroll,et al.  Treatment failure after primary and salvage therapy for prostate cancer , 2008, Cancer.

[21]  A. Partin,et al.  Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. , 2006, The Journal of urology.

[22]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[23]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[24]  William J Catalona,et al.  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. , 2004, The Journal of urology.

[25]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[26]  A. Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[27]  P. Saylor,et al.  Metabolic complications of androgen deprivation therapy for prostate cancer. , 2013, The Journal of urology.

[28]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[29]  C. Lawton.  Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial , 2010 .

[30]  A. Hanlon,et al.  Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[31]  J. Moul,et al.  Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. , 2008, The Journal of urology.

[32]  Dietmar Schnorr,et al.  Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. , 2006, Clinical chemistry.